Nanthealth LLC (NYSE:NH)’s share price was up 2.2% on Thursday . The company traded as high as $14.35 and last traded at $14.04, with a volume of 53,690 shares trading hands. The stock had previously closed at $13.74.

A number of equities analysts have weighed in on NH shares. Canaccord Genuity started coverage on Nanthealth in a research note on Monday, June 27th. They set a “buy” rating and a $17.00 price objective for the company. Cowen and Company started coverage on Nanthealth in a research note on Monday, June 27th. They set an “outperform” rating and a $19.00 price objective for the company. FBR & Co started coverage on Nanthealth in a research note on Monday, June 27th. They set an “outperform” rating and a $18.00 price objective for the company. Jefferies Group started coverage on Nanthealth in a research note on Monday, June 27th. They set a “buy” rating for the company. Finally, First Analysis started coverage on Nanthealth in a research note on Monday, June 27th. They set an “overweight” rating and a $18.00 price objective for the company. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $18.00.

The firm’s market cap is $7.61 billion. The company’s 50 day moving average price is $13.88 and its 200-day moving average price is $13.88.

In other news, major shareholder Healthcare Solution Allscripts bought 714,286 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $10,000,004.00. Following the completion of the purchase, the insider now owns 15,000,000 shares in the company, valued at approximately $210,000,000. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Patrick Soon-Shiong bought 357,143 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were purchased at an average price of $14.00 per share, with a total value of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.